A fragment-like approach to PYCR1 inhibition

Kirsty Milne, Jianhui Sun, Esther A. Zaal, Jenna Mowat, Patrick H.N. Celie, Alexander Fish, Celia R. Berkers, Giuseppe Forlani, Fabricio Loayza-Puch, Craig Jamieson, Reuven Agami

Research output: Contribution to journalArticle

Abstract

Pyrroline-5-carboxylate reductase 1 (PYCR1) is the final enzyme involved in the biosynthesis of proline and has been found to be upregulated in various forms of cancer. Due to the role of proline in maintaining the redox balance of cells and preventing apoptosis, PYCR1 is emerging as an attractive oncology target. Previous PYCR1 knockout studies led to a reduction in tumor growth. Accordingly, a small molecule inhibitor of PYCR1 could lead to new treatments for cancer, and a focused screening effort identified pargyline as a fragment-like hit. We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Structural activity studies have revealed the key determinants of activity, with the most potent compound (4) showing improved activity in vitro in enzyme (IC50 = 8.8 µM) and pathway relevant effects in cell-based assays.

LanguageEnglish
Pages2626-2631
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume29
Issue number18
Early online date25 Jul 2019
DOIs
Publication statusPublished - 15 Sep 2019

Fingerprint

Pyrroline Carboxylate Reductases
Oxidoreductases
Proline
Pargyline
Neoplasms
Oncology
Biosynthesis
Enzymes
Inhibitory Concentration 50
Oxidation-Reduction
Tumors
Assays
Screening
delta-1-pyrroline-5-carboxylate
Apoptosis
Molecules
Growth

Keywords

  • fragment-based drug discovery
  • iInhibitor
  • oncology
  • proline modulation
  • tool compound

Cite this

Milne, Kirsty ; Sun, Jianhui ; Zaal, Esther A. ; Mowat, Jenna ; Celie, Patrick H.N. ; Fish, Alexander ; Berkers, Celia R. ; Forlani, Giuseppe ; Loayza-Puch, Fabricio ; Jamieson, Craig ; Agami, Reuven. / A fragment-like approach to PYCR1 inhibition. In: Bioorganic and Medicinal Chemistry Letters . 2019 ; Vol. 29, No. 18. pp. 2626-2631.
@article{3a7f85ca9dff43598335a9e53461e08e,
title = "A fragment-like approach to PYCR1 inhibition",
abstract = "Pyrroline-5-carboxylate reductase 1 (PYCR1) is the final enzyme involved in the biosynthesis of proline and has been found to be upregulated in various forms of cancer. Due to the role of proline in maintaining the redox balance of cells and preventing apoptosis, PYCR1 is emerging as an attractive oncology target. Previous PYCR1 knockout studies led to a reduction in tumor growth. Accordingly, a small molecule inhibitor of PYCR1 could lead to new treatments for cancer, and a focused screening effort identified pargyline as a fragment-like hit. We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Structural activity studies have revealed the key determinants of activity, with the most potent compound (4) showing improved activity in vitro in enzyme (IC50 = 8.8 µM) and pathway relevant effects in cell-based assays.",
keywords = "fragment-based drug discovery, iInhibitor, oncology, proline modulation, tool compound",
author = "Kirsty Milne and Jianhui Sun and Zaal, {Esther A.} and Jenna Mowat and Celie, {Patrick H.N.} and Alexander Fish and Berkers, {Celia R.} and Giuseppe Forlani and Fabricio Loayza-Puch and Craig Jamieson and Reuven Agami",
year = "2019",
month = "9",
day = "15",
doi = "10.1016/j.bmcl.2019.07.047",
language = "English",
volume = "29",
pages = "2626--2631",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
number = "18",

}

Milne, K, Sun, J, Zaal, EA, Mowat, J, Celie, PHN, Fish, A, Berkers, CR, Forlani, G, Loayza-Puch, F, Jamieson, C & Agami, R 2019, 'A fragment-like approach to PYCR1 inhibition' Bioorganic and Medicinal Chemistry Letters , vol. 29, no. 18, pp. 2626-2631. https://doi.org/10.1016/j.bmcl.2019.07.047

A fragment-like approach to PYCR1 inhibition. / Milne, Kirsty; Sun, Jianhui; Zaal, Esther A.; Mowat, Jenna; Celie, Patrick H.N.; Fish, Alexander; Berkers, Celia R.; Forlani, Giuseppe; Loayza-Puch, Fabricio; Jamieson, Craig; Agami, Reuven.

In: Bioorganic and Medicinal Chemistry Letters , Vol. 29, No. 18, 15.09.2019, p. 2626-2631.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A fragment-like approach to PYCR1 inhibition

AU - Milne, Kirsty

AU - Sun, Jianhui

AU - Zaal, Esther A.

AU - Mowat, Jenna

AU - Celie, Patrick H.N.

AU - Fish, Alexander

AU - Berkers, Celia R.

AU - Forlani, Giuseppe

AU - Loayza-Puch, Fabricio

AU - Jamieson, Craig

AU - Agami, Reuven

PY - 2019/9/15

Y1 - 2019/9/15

N2 - Pyrroline-5-carboxylate reductase 1 (PYCR1) is the final enzyme involved in the biosynthesis of proline and has been found to be upregulated in various forms of cancer. Due to the role of proline in maintaining the redox balance of cells and preventing apoptosis, PYCR1 is emerging as an attractive oncology target. Previous PYCR1 knockout studies led to a reduction in tumor growth. Accordingly, a small molecule inhibitor of PYCR1 could lead to new treatments for cancer, and a focused screening effort identified pargyline as a fragment-like hit. We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Structural activity studies have revealed the key determinants of activity, with the most potent compound (4) showing improved activity in vitro in enzyme (IC50 = 8.8 µM) and pathway relevant effects in cell-based assays.

AB - Pyrroline-5-carboxylate reductase 1 (PYCR1) is the final enzyme involved in the biosynthesis of proline and has been found to be upregulated in various forms of cancer. Due to the role of proline in maintaining the redox balance of cells and preventing apoptosis, PYCR1 is emerging as an attractive oncology target. Previous PYCR1 knockout studies led to a reduction in tumor growth. Accordingly, a small molecule inhibitor of PYCR1 could lead to new treatments for cancer, and a focused screening effort identified pargyline as a fragment-like hit. We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Structural activity studies have revealed the key determinants of activity, with the most potent compound (4) showing improved activity in vitro in enzyme (IC50 = 8.8 µM) and pathway relevant effects in cell-based assays.

KW - fragment-based drug discovery

KW - iInhibitor

KW - oncology

KW - proline modulation

KW - tool compound

UR - http://www.scopus.com/inward/record.url?scp=85069684729&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2019.07.047

DO - 10.1016/j.bmcl.2019.07.047

M3 - Article

VL - 29

SP - 2626

EP - 2631

JO - Bioorganic and Medicinal Chemistry Letters

T2 - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 18

ER -